TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.~* Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.~* Have failed at least one standard therapy~* Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.~Exclusion Criteria:~* Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.~* Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).~* Uncontrolled active infection.~* Current use of prohibited medications~* Known HIV infection or active Hepatitis B or Hepatitis C virus infection~* Other hematologic/biochemistry requirements, as per protocol~* Use of investigational agent within last 14 days~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bomedemstat (Type: EXPERIMENTAL): Bomedemstat administered daily for 169 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented RCC with metastases.~* Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to disease progression or unacceptable treatment-related toxicity~Exclusion Criteria:~* Any prior systemic treatment for Renal Cell Carcinoma \[RCC\] other than 1 prior cytokine-based treatment regimen. Cytokine-based regimens containing thalidomide or an anti-angiogenesis agent are not allowed.~* Inability to take oral medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with Type 1 Gaucher disease regardless of treatment status who are enrolled in the International Collaborative Gaucher Group (ICCG) Gaucher Registry and who are cared for at one of the participating research sites.~Exclusion Criteria:~* Children under the age of 18 years~  * Patients with Type 3 Gaucher disease~ * Patients who have declined to be enrolled in the ICCG Gaucher Registry~ * Patients not cared for at one of the participating research sites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adults with Type 1 Gaucher disease (GD1) (Type: None): Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female ≥18 years of age;~* Rutherford Clinical Category 3, 4 \& 5;~* Life expectancy ≥ 1 year;~* Significant stenosis (≥70%)~* A patent inflow artery;~* Target vessel(s) diameter between 2 and 4 mm;~* Target vessel(s) reconstitute(s) at or above the ankle~Exclusion Criteria:~* Pregnant or planning on becoming pregnant;~* History of stroke within 3 months;~* History of MI, thrombolysis or angina within 30 days of enrollment;~* Planned major amputation (of either leg)~* Prior major amputation if amputation occurred less than one year prior to enrollment and if patient is not independently ambulating;~* GFR ≤ 30 ml/min per 1.73m2;~* Acute limb ischemia;~* In-stent restenosis of target lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lutonix DCB (Type: EXPERIMENTAL): Lutonix Paclitaxel Drug Coated Balloon
- PTA Catheter (Type: ACTIVE_COMPARATOR): Standard Uncoated PTA Catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Health workers in areas of care for patients with COVI-19~* Adults~* Men and women.~* That they agree to participate in the study by signing the letter of informed consent~Exclusion Criteria:~* Those who know that they have already suffered from COVID-19~* Those who have received a vitamin D supplement in the previous two weeks.~* Difficulty obtaining blood samples

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- cholecalciferol (Vitamin D) (Type: EXPERIMENTAL): cholecalciferol 4,000 IU orally daily (1 capsule) for 30 days
- Starch (Type: PLACEBO_COMPARATOR): Starch 500 mg orally daily (1 capsule) for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nefopam/Fentanyl Postoperative Intravenous Patient-Controlled-Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* those planned for elective open laparotomy under general anesthesia, who were classified as ASA physical status I-II~Exclusion Criteria:~* the presence of renal and hepatic disease, high risk of urinary retention, seizure history, known allergy to any of the medications used, current history of psychiatric disorder, or those presently taking psychotropic medications or monoamine oxidase inhibitors.~* Patients who could not understand verbal rating scale (VRS) and 11-points numeric rating scale (NRS) pain scores, or did not sign on informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nefopam(NF) group (Type: EXPERIMENTAL): Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
- Saline(SF) group (Type: PLACEBO_COMPARATOR): Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resection of at least the equivalent tissue volume of 1 anatomical segment of the liver~* Minor to moderate (oozing/diffuse) bleeding from the resection area persisting after conventional resection procedure and primary control of arterial pulsating bleeding or major venous hemorrhage by sutures, ligations, clips, vascular stapler, point electrocautery or focal radiofrequency ablation~* Need for additional supportive hemostatic treatment~* Expected ability to lightly press the trial treatment to the liver resection wound for 3 minutes~Exclusion Criteria:~* Indication for emergency surgery~* Known coagulopathy (as judged relevant by the investigator)~* Known or suspected hypersensitivity to any ingredient of the investigational medicinal products (e.g. human fibrinogen, human thrombin and/or collagen of any origin)~* Patient unwilling to receive blood products~* Known current alcohol or drug abuse~* Pregnancy, breastfeeding, no use of acceptable contraceptive method in females of childbearing potential~* Dry surgical field of the targeted application area~* Occurrence of any serious surgical complication~* Disseminated intravascular coagulopathy (DIC), i.e. microvascular bleeding~* Application of topical hemostatic material on the liver resection wound~* Radiofrequency precoagulation of the liver resection wound except focal radiofrequency ablation of vessels as primary hemostatic treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TachoSil® (Type: ACTIVE_COMPARATOR): TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
- Surgicel® Original (Type: ACTIVE_COMPARATOR): Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Treatment of Migraine With e-TNS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction)~* Having a migraine attack lasting at least 3 hours~* Migraine pain intensity stabilized for at least 1 hour~* Frontal, retro-, or peri- orbital headache.~Exclusion Criteria:~* Pregnant women~* Patients having received Botox treatment in the prior 4 months~* Patients having received supraorbital nerve blocks in the prior 4 months~* Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache~* Patients with only temporal or occipital headache~* Patients using opioid medication~* Patients having taken abortive migraine medication in the prior 3 hours~* Allodynia: intolerance to supraorbital neurostimulation (allodynia) that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 5 minutes of neurostimulation).~* Implanted metal or electrical devices in the head~* Cardiac pacemaker or implanted or wearable defibrillator~* Patient having had a previous experience with Cefaly®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active device (Type: EXPERIMENTAL): 60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
- Sham device (Type: SHAM_COMPARATOR): 60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Approaches to Malnutrition Enteropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 6 - 59 months, of either sex;~2. Inpatient in the paediatric wards of one of the research sites;~3. Hospitalised with Severe Acute Malnutrition (SAM, defined using WHO definition: weight-for-length z score of less than -3, or mid upper arm circumference of less than 11.5cm, and/or bilateral pedal oedema);~4. Clinically stable\*;~5. With written, informed consent from the primary caregiver(s); the child cannot be enrolled if the primary caregiver(s) cannot give consent.~   * Judged by the medical team on a case by case basis, but in general a child without shock, hypothermia, hypoglycaemia or reduced conscious level.~Exclusion Criteria:~1. Clinically unstable\*;~2. Less than 5kg body weight;~3. Neurological disability which would explain or partly explain poor feeding;~4. Oro-facial abnormalities which would explain or partly explain poor feeding;~5. Caregiver unwilling to consent to child HIV testing;~6. Haemoglobin concentration \< 6 g/dl at the time of enrolment;~7. Caregiver unwilling to remain in hospital for the duration of the study treatment;~8. Any underlying condition, other than HIV, which in the opinion of the investigator would put the subject at undue risk of failing study completion or would interfere with analysis of study results;~9. Contraindication to any of the trial treatments (e.g. allergy to cow's milk protein).~   * As assessed by the medical team on a case-by-case basis, but in general a clinically unstable state would include shock, hypothermia, hypoglycaemia or reduced conscious level.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Colostrum (Type: EXPERIMENTAL): Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
- GInNAC (Type: EXPERIMENTAL): N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
- Teduglutide (Type: EXPERIMENTAL): Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
- Budenoside (Type: EXPERIMENTAL): Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
- Standard care (Type: NO_INTERVENTION): Standard care following WHO guidelines for management of SAM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age 2 months to \< 11 years~2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, or rapid HIV antibody test ii. Children \< 18 months: Documentation will be DNA PCR confirmation only along with documentation of testing from the referral entity~3. ART-naïve patients eligible for ART initiation per WHO/Uganda guidelines (see Table 1) or Patients receiving first line ART regimen with NNRTI +2 NRTI with at least one HIV RNA \<400 copies/ml within the past 6 months~4. Agreement to come to the study clinic for any febrile episode or other illness~5. Agreement to avoid medications administered outside study protocol~6. Provision of informed consent by parent/guardian and agreement to have child's care at the clinical site~7. Lives within 50 km of study site~Exclusion criteria:~1. ART-naïve children: children or their mothers that have received any dose of Nevirapine in the past 24 months~2. Active medical problem requiring in-patient evaluation at the time of screening or enrollment~3. History of cardiac conduction disorder or known significant cardiac structural defect~4. Children receiving any disallowed medications (see section 4.3)~5. Moderate, Severe or Life-threatening (Grade 2, 3, or 4) AST or ALT found within 4 weeks prior to enrollment:~   * AST: \>113U/L (\>2.5xULN)~  * ALT: \>113U/L (\>2.5xULN)~6. Life-threatening (Grade 4) screening laboratory value found within 4 weeks prior to enrollment for the following:~   * Absolute neutrophil count: \<500 mm3~  * Hemoglobin: \<6.5 g/dL~  * Creatinine: \>3.5xULN~  * Platelets: \<25,000/mm3

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Lopinavir/ritonavir (LPV/r) +2 NRTI (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
- Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI (Type: ACTIVE_COMPARATOR): Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults \>/= 18 years of age (from the 18th birthday) at enrollment and older.~2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of investigational product.~3. Negative urine pregnancy test at Visit1 for all subjects who are of childbearing potential.~Exclusion Criteria:~1. Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.~2. History of microbiologically proven invasive disease caused by S pneumoniae.~3. Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.~4. Pregnant female subjects or breastfeeding female subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 60 years and above 20vPnC/Saline (Type: EXPERIMENTAL): 20vPnC and saline
- 60 years and above 13vPnC/PPSV23 (Type: ACTIVE_COMPARATOR): 13vPnC and PPSV23
- 50 through 59 years of age 20vPnC (Type: EXPERIMENTAL): 20vPnC
- 18 through 49 years of age 20vPnC (Type: EXPERIMENTAL): 20vPnC
- 50 through 59 years of age 13vPnC (Type: ACTIVE_COMPARATOR): 13vPnC
- 18 through 49 years of age 13vPnC (Type: ACTIVE_COMPARATOR): 13vPnC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Neuropathic Pain by mémantine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years old~* patient suffering breast cancer with mastectomy/tumorectomy with or within cleaning 2 weeks after inclusion with or within pre-emptive chemotherapy~Exclusion Criteria:~* Against-indication at memantine administration : hypersensitivity at active substance or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac insufficiency~* Diabetic patient (Type I and II)~* Patient with medical or surgical antecedents~* Patient receiving treatment with amantadine, ketamine, dextrometorphan, L-Dopa, dopaminergic, anticholinergic agonists, barbiturate, neuroleptic, IMAO, antispastic agents, dantrolen or baclofen, phenitoin, cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine, hydrochlorothiazide, warfarine~* Patient with alcohol addiction~* Woman in childbearing age not using effective contraceptive method, pregnant or lactating woman~* Patient who participated in another clinical trial, located in exclusion period or received benefits \> 4500 euros during 12 months before the beginning of trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete